PRECISION BIOSCIENCES INC

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

DTIL$9.68-8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Operations

(In thousands, except share and per share amounts)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2026	2025	2026	2025
Revenue	$—	$13	$10,838	$60
Operating expenses
Research and development	12,745	13,352	38,249	39,708
General and administrative	7,683	7,328	21,253	25,008
Total operating expenses	20,428	20,680	59,502	64,716
Operating loss	(20,428)	(20,667)	(48,664)	(64,656)
Other income (expense):
(Loss) gain from equity method investment	—	(591)	—	86
Loss on changes in other fair value adjustments	(456)	(3)	(3,651)	(2,418)
Gain (loss) on change in fair value of warrant liability	12,724	(1,179)	(8,274)	(1,230)
Interest expense	(307)	(362)	(918)	(1,074)
Interest income	881	1,027	2,823	3,466
Gain (loss) on disposal of assets	—	3	5	(31)
Total other income (expense)	12,842	(1,105)	(10,015)	(1,201)
Net loss	$(7,586)	$(21,772)	$(58,679)	$(65,857)
Net loss per share
Basic	$(0.28)	$(1.84)	$(2.26)	$(6.14)
Diluted	$(0.28)	$(1.84)	$(2.26)	$(6.14)
Weighted-average shares of common stock outstanding
Basic	27,433,353	11,818,145	25,985,060	10,728,199
Diluted	27,433,353	11,818,145	25,985,060	10,728,199

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.